Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study

Abstract Background Efficacy of second-line treatments after first-line platinum-based chemotherapy in advanced cervical cancer is modest. This open-label, single-arm, multicentre, proof-of-concept phase 2 study evaluated fruquintinib plus sintilimab in advanced cervical cancer. Methods Patients rec...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiaohua Wu, Danbo Wang, Jing Wang, Yi Huang, Tienan Yi, Guiling Li, Jieqing Zhang, Keming Wang, Yu Kang, Anwen Liu, Xiaotian Han, Xuemei Ren, Li Li, Runfeng Yang, Quan Li, Qing Yang, Bingbing Zhao, Juan Wang, Hanjie Yi, Yue Tan, Keyan Chen, Puhan Lu, Haiyan Shi, Panfeng Tan, Songhua Fan, Michael M. Shi, Weiguo Su
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2026-04-01
Edice:	Communications Medicine
On-line přístup:	https://doi.org/10.1038/s43856-026-01572-z
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!